Stroke prevention in atrial fibrillation: Do we still need warfarin?

Current Opinion in Neurology

Volumn 25, Issue 1, 2012, Pages 27-35

  Diener, Hans Christoph ^a   Weber, Ralph ^a   Lip, Gregory Y H ^b   Hohnloser, Stefan H ^c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

apixaban; atrial fibrillation; dabigatran; rivaroxaban; stroke; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIFUNGAL AGENT; APIXABAN; ATORVASTATIN; AZD 0837; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; KETOCONAZOLE; PHENPROCOUMON; PLACEBO; QUINIDINE; RIFAMPICIN; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EMBOLISM; EPISTAXIS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; MORTALITY; PREVENTION STUDY; REVIEW; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS AS TOPIC; DECISION MAKING; FACTOR XA; HUMANS; RISK FACTORS; STROKE; THROMBIN; VITAMIN K; WARFARIN;

EID: 84855700916     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32834e604a     Document Type: Review

References (59)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22:983-988.
2. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36:1115-1119. (Pubitemid 40803473)
3. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133 (6 Suppl):546S-592S. (Pubitemid 351892972)
4. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001; 285:2370-2375. (Pubitemid 32424106)
5. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69:546-554.
6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867. (Pubitemid 351650486)
7. Jorgensen HS, Nakayama H, Reith J, et al. Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology 1997; 48:891-895.
8. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255-1262.
9. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151:297-305.
10. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133 (6 Suppl): 160S-198S. (Pubitemid 351892967)
11. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008; 29:155-165.
12. Hylek E, Singer D. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120:897-902. (Pubitemid 24179151)
13. Oden A, Fahlen M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006; 117:493-499. (Pubitemid 43326133)
14. Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010; 41:397-401.
15. Lakshminarayan K, Solid CA, Collins AJ, et al. Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992-2002). Stroke 2006; 37:1969-1974. (Pubitemid 44309888)
16. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch Intern Med 2003; 163:1580-1586. (Pubitemid 36835103)
17. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160:41-46. (Pubitemid 30040971)
18. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123:638-645; e4.
19. ACTIVE Writing Group on behalf of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367:1903-1912.
20. Connolly S, Yusuf S, Budaj A, et al. Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J 2006; 151:1187-1193.
21. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066-2078.
22. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64:292-303. (Pubitemid 47283865)
23. Wienen W, Stassen JM, Priepke H, et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98:155-162. (Pubitemid 47078782)
24. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45:555-563. (Pubitemid 40562946)
25. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15 (1 Suppl):9S-16S.
26. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36:386-399. (Pubitemid 351185753)
27. Stangier J, Rathgen K, Stahle H, et al. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 2009; 9:59-68.
28. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol 2007; 100:1419-1426. (Pubitemid 47576022)
29. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157:805-810; 10 e1-10 e2.
30. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
31. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875-1876.
32. Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9:1157-1163.
33. Diener H, Connolly S, Ezekowitz M, et al. Dabigatran compared to warfarin in patients with atrial fibrillation and prior TIA or stroke: results of RE-LY [abstract]. American Stroke Association International Stroke Conference 2010; 26 February 2010; San Antonio, TX. Abst. 195.
34. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-termanticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363-2372.
35. Beasley BN, Unger EF, Temple R. Anticoagulant options: why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011; 364:1788-1790.
36. Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011; 27:74-90.
37. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369-2429.
38. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:104-123.
39. Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009; 30:2897-2907.
40. Olsson SB, Rasmussen LH, Tveit A, et al. Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost 2010; 103:604-612.
41. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78:412-421. (Pubitemid 41393676)
42. Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37:1056-1064.
43. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007; 47:218-226. (Pubitemid 46146488)
44. Mismetti P, Laporte S. Rivaroxaban: clinical pharmacology. Ann Fr Anesth Reanim 2008; 27 (3 Suppl):S16-S21.
45. Perzborn E, Roehrig S, Straub A, et al. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010; 30:376-381.
46. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban: an oral, direct factor Xa inhibitor: in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47:203-216.
47. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2010; 70:703-712.
48. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
49. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
50. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32:2387-2394.
51. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37:74-81.
52. Shantsila E, Lip GY. Apixaban, an oral, direct inhibitor of activated factor Xa. Curr Opin Investig Drugs 2008; 9:1020-1033.
53. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010; 38:448-458.
54. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159:331-339.
55. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364:806-817.
56. Hylek E. DU-176b, an oral, direct factor Xa antagonist. Curr Opin Investig Drugs 2007; 8:778-783. (Pubitemid 47345534)
57. Zafar MU, Vorchheimer DA,Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 2007; 98:883-888. (Pubitemid 47555083)
58. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104:633-641.
59. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010; 160:635-641.